TissUse offers high-value service contracts to create custom solutions for safety evaluation of drugs, cosmetics and chemicals, and pre-clinical human disease modelling. Any new chip design serving customer needs with a specific organ arrangement can be prototyped and produced at short notice due to a proprietary rapid prototyping procedure established at TissUse.

The versatile TissUse approach addresses multiple organs & tissues to make the right chip for the right assay.

TissUse Multi organ Chip assay

Drug development

Our goal is to deliver the tools to accelerate drug development through these stages together with all the scientists over the world towards patient’s benefit. Our experienced team with long-standing expertise in Multi-Organ-Chip assay development (>50 MOC publications) will design your flexible, efficient and reliable assay for safety or efficacy testing.

  • Safety: Identify hazards before moving on to exposing organisms with your substance of interest.
  • Efficacy: Get early and strong indication of your substance performance early in the development process.

Examples of established assays by TissUse

  DMPK / Safety / Hazard identification
  Mode of Action / Efficacy

No. Organ model Schematic Context of use Level of readiness Species
1 Blood-Brain-barrier – Neuro – Liver BBB permeability, organ toxicity, metabolite neurotoxicity III Human
2 Bone marrow Bone marrow toxicity, chemotherapy scheduling, erythropoiesis III Human
3 Hair follicle Hair growth agents III Human
4 Intestine – Liver Absorption, metabolism III Human
5 Intestine – Liver – Kidney – Neuro ADME-profiling, PBPK, first-path metabolism, primary & secondary organ toxicity III Human
6 Intestine – Liver – Kidney – Neuro + Blood-Brain-Barrier ADME-profiling, PBPK, first-path metabolism, primary & secondary organ toxicity III Human
7 Lung – Liver Hazard identification III Human
8 Pancreas – Liver Diabetes target finding, mathematical modeling III Human
9 Skin – Liver Compound PK/PD, skin irritancy, toxicity, first-path metabolism III Human
10 Skin – Tumor Anti-tumor antibodies III Human
11 Thyroid – Liver Endocrine disruption III Human vs. Rat
12 Liver Drug evaluation II Human
13 Lung Nanoparticle toxicity II Human
14 Skin – Liver – Thyroid Repeated dose topical and systemic administration II Human
15 Testis – Liver Testicular toxicity II Human
16 Vasculature – Pancreas – Tumor Anti-tumor therapy II Human
17 Bone Nanoparticle toxicity I Human
18 Cardio – Liver Metabolite cardiotoxicity I Human
19 Endometrium Physiology/Pathology I Human
20 Intestine – Skeletal muscle Muscle growth agents I Human vs. Pig
21 Kidney (glomerulus) – Liver Therapeutic effect of MSC-derived extracellular vesicles I Human
22 Kidney (proximal tubules) – Liver Repeated dose proximal tubules toxicity I Human
23 Neuro – Liver Metabolite neurotoxicity I Human
24 Immunocompetent Skin – Gingiva Skin and oral toxicity I Human
25 Skin including dermal papillae Skin sensitizer I* Human
26 Skin – Leukocytes Allograft rejection therapies I Human
27 Tumor (DLBCL) – Liver Personalized automatized cancer treatment I Human

III  Assay established, available for testing/assay transfer
II   Model established, available for assay development
I    Proof of Concept, available for joint development or *independently developed by partner lab

Choose your Multi-Organ-Chip and organ combination